v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Cash flows from operating activities:          
Net loss     $ (11,689,201) $ (10,143,939)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization     17,079 16,286  
Stock-based compensation     302,955 369,117  
Foreign currency (gain) loss $ (2,847) $ 5,691 (13,511) 86,618  
Changes in operating assets and liabilities:          
Prepaid expenses and other current and noncurrent assets     369,461 517,745  
Accounts payable     545,060 (715,625)  
Accrued expenses     705,215 (63,349)  
Net cash used in operating activities     (9,762,942) (9,933,147)  
Cash flows from investing activities:          
Purchases of property and equipment     (15,401)    
Net cash used in investing activities     (15,401)    
Cash flows from financing activities:          
Proceeds from the exercise of warrants     342,000    
Proceeds from issuance of common stock     35,598,881 834,397  
Common stock issuance costs     (2,912,439) (35,729)  
Net cash provided by financing activities     33,028,442 798,668  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (2,443) 3,406  
Change in cash, cash equivalents and restricted cash     23,247,656 (9,131,073)  
Cash, cash equivalents and restricted cash-beginning of year     14,640,533 22,890,055 $ 22,890,055
Cash, cash equivalents and restricted cash-end of period 37,888,189 13,758,982 37,888,189 13,758,982 14,640,533
Reconciliation of cash, cash equivalents and restricted cash          
Cash and cash equivalents 37,846,363 13,718,052 37,846,363 13,718,052 14,599,347
Restricted cash 41,826 40,930 41,826 40,930 41,186
Total cash, cash equivalents and restricted cash $ 37,888,189 $ 13,758,982 37,888,189 13,758,982 $ 14,640,533
Non-cash investing and financing activities:          
Purchase of property and equipment included in accounts payable     $ 4,314    
Conversion of Series A convertible preferred stock to common stock       $ 583,702